Navigation Links
Anesiva Announces Second Quarter 2008 Financial Results and Update
Date:8/7/2008

several weeks following

treatment.

Additional Development

-- Anesiva out-licensed worldwide rights to its NF-kappa B Decoy program

to Transcription Factor Therapeutics, Inc. Anesiva will receive an

upfront licensing fee, and will be entitled to receive milestone

payments totaling up to $114 million if two products are

commercialized. NF-kappa B is a protein implicated in autoimmune and

inflammatory disease processes, therapeutic areas outside Anesiva's

current focus on pain management.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first commercial product, Zingo(TM), is available in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. For full Zingo prescribing information and other information, visit http://www.zingo.com. An sNDA is under review at FDA to expand the Zingo label indication to include adults.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in Phase 3 clinical trials for the management of acute pain following orthopedic surgeries. Adlea has been shown to reduce pain after only a single administration for up to weeks to months in multiple settings based on the results of several mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward-Looking Statements
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest ... research medicinal plants and therapeutic derivatives thereof has ... professionals, and researchers about the challenges of adulterated ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society for ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... 2 HUYA Bioscience,International (HUYA), a rapidly ... key disease-fighting drugs sourced from China,announced today ... stage anti-arrhythmic,compound from the prestigious Shanghai Institute ... The compound, HBI-3000 or sulcardine, exhibits ...
... Cost-Effective, Time-Saving, ATLANTA, Oct. 1 ... CliniCom(TM), a revolutionary software platform,designed to assess ... CliniCom(TM), an intuitive, computer assisted intake ... health settings, gathers information,directly from patients and ...
... Center,has awarded a five-year, $120-million extension of its ... also known,as NSBRI, of Houston. Under the extension, ... biomedical research in support of a,long-term human presence ... cooperative agreement began April 1, 1997, with,a value ...
Cached Biology Technology:HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica 2HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica 3Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology 2Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology 3
(Date:4/24/2014)... bend light, acting as a lens. Now, by exploiting ... to create inexpensive high quality lenses that will cost ... so inexpensive, the lenses can be used in a ... the field, scientific research in the lab and optical ... "What I,m really excited about is that it opens ...
(Date:4/23/2014)... heating may contribute to early fetal death according to ... Institute of Children,s Hospital Los Angeles and Ulaanbaatar, Mongolia ... In a paper published today in the journal ... statistical correlations" between seasonal ambient air pollutants and pregnancy ... one of the highest levels of air pollution of ...
(Date:4/23/2014)... news release is available in French and ... , Montreal, 23 April 2014Today, the CEC released its ... Binational Collaborative Approach to Conservation, which identifies 29 priority ... border that includes 11 different protected areas in the ... unique, highly diverse arid and semi-arid habitats inhabited by ...
Breaking Biology News(10 mins):Bake your own droplet lens 2Bake your own droplet lens 3Pollutants from coal-burning stoves strongly associated with miscarriages in Mongolia 2Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3
... FL November 18, 2010 For Immediate Release - ... Palm Beach residents Judy and J. John Goodman, M.D., to ... Professor Thomas Kodadek, Ph.D., in the development of a new ... as the Scripps Research graduate program endowment. "We are ...
... Nov. 18, 2010 AMDeC, the Academy ... Technologies has renewed and expanded its agreement to offer ... on a number of products important for genomics and ... academic medical research institutions in the New York region. ...
... disorder characterized by progressive loss of vision that in ... stage. , In a ChIP-Seq based approach, the researchers ... Crx (Cone-rod homeobox) in the expression of retina-specific genes ... perception. In-depth analysis of Crx mediated regulation in photoreceptors ...
Cached Biology News:Agilent Technologies Expands Agreement to Offer AMDeC Members Preferential Pricing on Products Through AMDeC F.I.R.S.T.™ Vendor Partnership Program 2Agilent Technologies Expands Agreement to Offer AMDeC Members Preferential Pricing on Products Through AMDeC F.I.R.S.T.™ Vendor Partnership Program 3Transcription factor scan identifies genetic cause for inherited blindness 2
Request Info...
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
... are designed for use with the ProQuest ... MaV203 contains deletions in the endogenous GAL4 ... two-hybrid systems. The strain also has leu2 ... bait and prey vectors. MaV203 contains three ...
Mouse monoclonal [CAT-1] to Chloramphenicol Acetyltransferase ( Abpromise for all tested applications)....
Biology Products: